Heme/Onc News Profile picture
CME experts Sara Fagerlie, PhD, CHCP & Mindy Tanzola, PhD have joined forces at Front Row to share the latest heme/onc news with clinicians and educators
Sep 13 6 tweets 6 min read
#ESMO22 final Presidential Symposium III presentation, #IPSOS, evaluating atezolizumab vs single-agent chemotherapy in pts with advanced NSCLC unsuitable for 1L standard platinum-based chemotherapy, N=453, primary EP: OS ImageImage #ESMO22 #IPSOS with a median f/u of 41 mo, atezolizumab monotherapy resulted in significantly improved OS (mOS: 10.3 vs 9.3 mo; HR-0.78; P=.028). The improved was seen across subgroups and independent of PD-L1 expression ImageImage
Sep 13 7 tweets 8 min read
#ESMO22 Presidential Symposium III continued with the eagerly awaited #CodeBreak200 evaluating sotorasib vs docetaxel in pts w/ locally advanced or metastatic KRAS G12C-mutated NSCLC (N=345) presented by @MLJohnsonMD2 from @SarahCannonDocs Image #ESMO22 #CodeBreak200 met it's primary EP of improved PFS by BICR with a median f/u of 17.7 mo. Median PFS: 5.6 vs 4.5 mo, HR=0.66, P=.002 ImageImage
Sep 13 6 tweets 6 min read
#ESMO22 COSMIC-313 presented by @DrChoueiri Triplet therapy with cabo/nivo/ipi vs cabo/nivo for patients with advanced TN advanced intermediate or poor-risk #RCC. Primary EP: PFS; N=855 Image #ESMO22 #COSMIC313: Longer PFS with triplet vs doublet. mPFS NR vs 11.3 mo with benefit seen in most predefined subgroups #RCC ImageImageImage
Sep 10 8 tweets 4 min read
#ESMO22 Presidential Symposium 1 LBA3 TIL vs ipilimumab for advanced melanoma, phase 3 study @HaanenJohn @OncoAlert @myESMO Unresectable stage IIC-IV melanoma progression with a max of 1 line of prior systemic treatment (not ipi), N = 168, randomized 1:1 TIL vs ipilimumab. Primary EP = PFS; Most pts had prior anti PD-1 treatment ImageImageImage